Ethoxyquin prevents chemotherapy‐induced neurotoxicity via Hsp90 modulation
- 1 December 2013
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 74 (6), 893-904
- https://doi.org/10.1002/ana.24004
Abstract
Objective Peripheral neurotoxicity is a major dose‐limiting side effect of many chemotherapeutic drugs. Currently there are no effective disease‐modifying therapies for chemotherapy‐induced peripheral neuropathies, but these side effects of chemotherapy are potentially ideal targets for development of neuroprotective therapies, because candidate drugs can be co‐ or preadministered before the injury to peripheral axons takes place. Methods We used a phenotypic drug screening approach to identify ethoxyquin as a potential neuroprotective drug and carried out additional biochemical experiments to identify its mechanism of action. Results We validated the screening results with ethoxyquin and its derivatives and showed that they prevented paclitaxel‐induced peripheral neuropathy without blocking paclitaxel's ability to kill tumor cells. Furthermore, we demonstrated that ethoxyquin acts by modulating the chaperone activity of heat shock protein 90 (Hsp90) and blocking the binding of 2 of its client proteins, ataxin‐2 and Sf3b2. Ethoxyquin‐induced reduction in levels of both of these proteins resulted in prevention of axonal degeneration caused by paclitaxel. Interpretation Ethoxyquin and its novel derivatives as well as other classes of small molecules that act as Hsp90 modulators may offer a new opportunity for development of drugs to prevent chemotherapy‐induced axonal degeneration. Ann Neurol 2013;74:893–904Funding Information
- Foundation for Peripheral Neuropathy
- Dr Miriam and Sheldon Adelson Medical Research Foundation
- NIH National Institute of Neurological Diseases and Stroke (NS43991)
- Johns Hopkins Brain Sciences Institute
This publication has 44 references indexed in Scilit:
- Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathyExperimental Neurology, 2012
- Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathiesFuture Medicinal Chemistry, 2011
- Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALSNature, 2010
- Heat shock protein 90 in neurodegenerative diseasesMolecular Neurodegeneration, 2010
- Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxelPain, 2009
- KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic CellsMolecular Pharmacology, 2009
- Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cellsExperimental Neurology, 2008
- Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal lineJournal of the Peripheral Nervous System, 2007
- Molecular Chaperones and Protein Quality ControlCell, 2006
- Wlds mice are resistant to paclitaxel (taxol) neuropathyAnnals of Neurology, 2002